Sponsored by

VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Jeff Sessions

Status
Not open for further replies.
Well, ole' El Jeffe is a gift that just keeps on giving....sort of like gonorrhea or psoriasis. sigh


Defying Congress, Jeff Sessions Keeps Blocking Medical Marijuana Research
Two years after accepting applications, the DEA has yet to grant licenses to growers.



It's been almost two years since the Drug Enforcement Administration (DEA) began accepting applications for new growers of research cannabis, and two dozen applicants are still in regulatory limbo.


Since the DEA announced in August 2016 that it would end the federal monopoly on producing cannabis for scientific research in the United States, growers, investors, researchers, applicants, and even members of Congress have sought to understand why a relatively simple licensing review process has stretched on for nearly two years. The answer is pretty straightforward: Attorney General Jeff Sessions, for reasons he has not publicly disclosed, decided to intervene in a process that has historically not involved the attorney general in order to stop the DEA from issuing licenses to growers.


While the Controlled Substances Act gives the attorney general regulatory authority over scheduled drugs, that authority has historically been delegated to the DEA, which is part of the Justice Department. The DEA has a whole division, in fact, dedicated to "investigat[ing] the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs."




Members of Congress are not happy with Sessions' obstruction of the licensing process. In April, Sens. Orrin Hatch (R–Utah) and Kamala Harris (D–Calif.) sent the attorney general a letter in which they asked him to provide the Senate with a timeline for processing applications from potential manufacturers of research marijuana. They also asked the DOJ to update applicants on the review process. Both actions, Hatch and Harris suggested, should be completed by May 15, 2018. Not only did the DOJ miss that deadline, but it doesn't seem interested in playing catch-up.


Four license applicants I interviewed in late June told me they've received no official updates from either the DEA or the DOJ in months. Applicants who have spoken to congressional offices working on this issue say their contacts are equally frustrated by Sessions' obstruction of the DEA's licensing process.


(Reason obtained the identities of the 26 initial applicants through a Freedom of Information Act request to the DEA. Reason is not identifying which applicants provided information for this story so as not to jeopardize their chances of approval. )


"No 'formal' communication for months," one applicant told me by email. "They do answer questions I've asked, although on a limited basis."


"No formal communication," another told me. "Hoping to hear more soon."


"Just silence," a third applicant told me over email.


The Hatch-Harris letter captures both the widespread support for studying cannabis and the disproportionate power Sessions has to maintain the status quo. "Expanded research has been called for by President Trump's Surgeon General, the Secretary of Veterans Affairs, the FDA, the CDC, the National Highway Safety Administration, the National Institute of Health, the National Cancer Institute, the National Academies of Sciences, and the National Institute on Drug Abuse," the senators wrote. "In order to facilitate such research, scientists and lawmakers must have timely guidance on whether, when, and how these manufacturers' applications will be resolved."


The rapid pace of marijuana legalization at the state level, meanwhile, might seem to lessen the need for federally licensed growers of research cannabis. Can't researchers just use the myriad cannabis products available in the 30 states that allow recreational or medical use? They cannot.


Researchers who want to test cannabis products in humans must comply with federal regulations governing the handling of Schedule I controlled substances. Those regulations require researchers who would like to use domestically produced marijuana to obtain their material from a federally licensed grower. For decades now, there has been only one such grower: Mahmoud ElSohly at the University of Mississippi, who operates under a contract with the National Institute on Drug Abuse (NIDA). The hundreds of researchers who are licensed by the federal government to study marijuana in the U.S. must use material obtained from NIDA, despite credible concerns about quality control and the agency's ability to provide material that reflects the diversity of products available to consumers in medical and recreational dispensaries across the country.


No other field of drug research or development requires that all pharmaceutical companies and academic institutions that would like to source their materials domestically get them from one person chosen by the federal government. To see the impact on the U.S. drug industry, one need look no further than the U.K., which produced Epidiolex, the first marijuana-derived drug to ever be approved by the Food and Drug Administration.


Could GW Pharmaceuticals, the maker of Epidiolex, have brought its drug to market if its research had used cannabis grown at the University of Mississippi? Stephen Schultz, the company's vice president of investor relations, wouldn't speculate. He did say, however, that the U.K.'s cannabis regulations are essential to the company's drug development strategy. "We develop medicines that have a very specific cannabinoid profile," Schultz said. "So it is very important that we be in complete control of creating our medicines, from growing to extracting."


What's more, it won't be possible to get FDA approval for a cannabis-derived medicine made in the United States until new manufacturers are approved, since the material used in Phase III clinical trials must be identical to the material used in the medicine. In other words, NIDA marijuana cannot be used in Phase III trials.


In August 2016, it seemed like the U.S. might finally allow a market for research cannabis. That month, the DEA, which for years had resisted attempts to create such a market, announced that it would begin accepting applications for additional licenses to manufacture research marijuana. "Although no drug product made from marijuana has yet been shown to be safe and effective," the notice in the Federal Register said, the DEA "fully supports expanding research into the potential medical utility of marijuana and its chemical constituents."


Some two dozen entrepreneurs and companies submitted lengthy applications in the months that followed that announcement. Many submitted additional information at the DEA's request. Two applicants told me they'd raised millions in funding, and several others said they'd made intellectual property arrangements with cannabis growers and researchers overseas. Plots of land were scouted and buildings were leased.


But enthusiasm quickly gave way to anxiety after Sessions was confirmed as attorney general in February 2017. That August, anxiety turned to dread when The Washington Post reported that Acting DEA Administrator Chuck Rosenstein had resigned after butting heads with Sessions over research cannabis. Rosenstein was reportedly in favor of approving new licenses, but Sessions brought the review to a screeching halt.


The Washington Post story eventually made its way to Hatch, who asked Sessions at a hearing in October 2017 why the DOJ had yet to license new growers of cannabis for pharmaceutical research. During their brief exchange, Sessions told Hatch it would be "healthy to have some more competition in the supply" of research marijuana, but the DOJ was not going to approve all 26 applicants. I contacted Hatch's office twice for comment but received no response.


Sessions suggested that the DEA lacked the capacity to supervise even a handful of additional cannabis manufacturers. That claim sounds spurious considering that the DEA routinely approves applications to manufacture Schedule I and II substances other than marijuana. The agency approved eight such manufacturing applications in June 2018, seven in May 2018, eight in April 2018, and three in February 2018. (One applicant familiar with the DEA's licensing process told me the cost of supervising additional license holders is probably marginal.)


Senators questioned the attorney general again in April 2018. At that hearing, Sessions came up with another excuse for not allowing the DEA to move forward. This time, he claimed approving additional marijuana growers might violate a United Nations treaty signed by the U.S. This claim is almost certainly not true even under the most literal and conservative reading of that treaty.


One more deadline looms. Hatch and Harris would like to see Sessions act on all outstanding applications, either approving or rejecting them, by August 11, 2018, the two-year anniversary of the DEA's announcement in the Federal Register. By comparison, it took the DOJ less than six months to process the controlled substance manufacturing applications it approved in June, one of which was for making synthetic marijuana.


If Sessions blows the August deadline, he won't just be smiting a crop of would-be cannabis entrepenuers. He will be standing in the way of medical progress and punishing patients and their families in the process.
Other countries will be 1st in medical research.
 
Other countries will be 1st in medical research.

Other countries ARE ALREADY first in medical MJ research...Israel for example, yeah?
 
IN 1963 an Isralie discovered THC.

Kind regards
Didn't know that but I did know that they have been a leader in MJ research. Thanks for the facts, my friend.

Hope all is well with you. You going on a trip to France soon? Do I remember that correctly?

:sunbathing:
 
Politics
Sessions Says States Are Free To Legalize Marijuana, But DOJ Can Enforce Federal Law

States are free to legalize marijuana, U.S. Attorney General Jeff Sessions said on Thursday, but his department plans to continue enforcing federal prohibition anyway.

“Personally my view is that the American republic will not be better if there are marijuana sales on every street corner,” Sessions said in response to a reporter’s question. “But states have a right to set their own laws and will do so.”

Sessions, speaking at a press conference in Boston about unrelated fraud prosecutions, said that when it comes to marijuana, “we’ll enforce the federal law.”

“The federal law remains the law of the United States.”

A growing number of states are moving to legalize marijuana for recreational or medical use.

But while federal cannabis prohibition remains on the books for now, momentum for reform is gaining traction in Congress.

Last month, President Trump voiced support for bipartisan legislation that would let states enact their own marijuana policies without federal interference.
 
This frakin guy just doesn't get it.


Jeff Sessions says federal government may override states’ marijuana laws

The Attorney General remains steadfast in his dedication to cracking down on cannabis.

In a press conference in Boston today, US Attorney General Jeff Sessions announced that a federal sting operation resulted in the arrest of more than two dozen people on charges of immigration document and benefit fraud. But while the focus of the presser was on alleged immigration fraud, reporters took the opportunity to question Sessions about the Department of Justice’s stance on states with legal marijuana.

Massachusetts, of course, legalized marijuana for adult use in November 2016. Sessions replied by reiterating his position that the US DOJ would continue to follow and enforce the federal ban on cannabis.

AG Jeff Sessions Renews Threat of Federal Crackdown on Legal Marijuana
Voters in Massachusetts legalized adult-use cannabis nearly two years ago. And while home cultivation and gifting cannabis are now legal, the state has yet to set up its retail industry.

But it’s close, and with the licensing process currently underway and the first retail permits already issued, the federal government’s stance on states’ marijuana laws is clearly crucial for Massachusetts at this particular juncture.

In response to reporters’ questions about that stance, Sessions stopped short of announcing that the Department of Justice had any enforcement actions in the works.

Instead, Sessions renewed the same kind of vague threats he issued in January of this year, when the DOJ rescinded the Obama-era Cole Memo, essentially a “hands off” policy toward states with legal cannabis programs.

“States have a right to set their own laws and will do so, and we will follow the federal law,” Sessions said. But the exact sense of “follow” wasn’t specified.

All Sessions added was that it was his personal view that “the American republic will not be better if there are marijuana sales on every street corner”. It’s hard to imagine dispensariesachieving Starbucks-like density, however, especially in Massachusetts. In fact, most of Massachusetts’ municipalities have banned marijuana retail.

Sessions’ Comments Aren’t Worrying Cannabis Regulators in MA
Despite the Attorney General’s obstinacy on the legal marijuana issue, state regulators in Massachusetts aren’t concerned about any looming enforcement actions once the state’s retail sales come online.

Even the chairperson of the Cannabis Control Commission, Steve Hoffman, says Massachusetts’ program doesn’t have anything to fear from Sessions’ comments.

Hoffman’s confidence stems from a statement by federal attorney Andrew Lelling. Lelling is a prosecutor who reports directly to Attorney General Sessions. And two weeks ago, Lelling issued a statement that, from Hoffman’s view, sounded a lot like the Cole Memo guidance issued by Obama’s DOJ.

According to Lelling, federal prosecutors are prioritizing three areas of marijuana law enforcement. First, ensuring legal cannabis surpluses aren’t diverted to illegal markets. Second, targeting operators who distribute cannabis to minors. And finally, hunting down criminal organizations that traffic cannabis across state lines.

Hoffman says Massachusetts regulators are already building in ways to address the Department of Justice’s major concerns. He believes that will be enough to keep Massachusetts out of Sessions’ drug-war crosshairs.
 
This frakin guy just doesn't get it.


Jeff Sessions says federal government may override states’ marijuana laws

The Attorney General remains steadfast in his dedication to cracking down on cannabis.

In a press conference in Boston today, US Attorney General Jeff Sessions announced that a federal sting operation resulted in the arrest of more than two dozen people on charges of immigration document and benefit fraud. But while the focus of the presser was on alleged immigration fraud, reporters took the opportunity to question Sessions about the Department of Justice’s stance on states with legal marijuana.

Massachusetts, of course, legalized marijuana for adult use in November 2016. Sessions replied by reiterating his position that the US DOJ would continue to follow and enforce the federal ban on cannabis.

AG Jeff Sessions Renews Threat of Federal Crackdown on Legal Marijuana
Voters in Massachusetts legalized adult-use cannabis nearly two years ago. And while home cultivation and gifting cannabis are now legal, the state has yet to set up its retail industry.

But it’s close, and with the licensing process currently underway and the first retail permits already issued, the federal government’s stance on states’ marijuana laws is clearly crucial for Massachusetts at this particular juncture.

In response to reporters’ questions about that stance, Sessions stopped short of announcing that the Department of Justice had any enforcement actions in the works.

Instead, Sessions renewed the same kind of vague threats he issued in January of this year, when the DOJ rescinded the Obama-era Cole Memo, essentially a “hands off” policy toward states with legal cannabis programs.

“States have a right to set their own laws and will do so, and we will follow the federal law,” Sessions said. But the exact sense of “follow” wasn’t specified.

All Sessions added was that it was his personal view that “the American republic will not be better if there are marijuana sales on every street corner”. It’s hard to imagine dispensariesachieving Starbucks-like density, however, especially in Massachusetts. In fact, most of Massachusetts’ municipalities have banned marijuana retail.

Sessions’ Comments Aren’t Worrying Cannabis Regulators in MA
Despite the Attorney General’s obstinacy on the legal marijuana issue, state regulators in Massachusetts aren’t concerned about any looming enforcement actions once the state’s retail sales come online.

Even the chairperson of the Cannabis Control Commission, Steve Hoffman, says Massachusetts’ program doesn’t have anything to fear from Sessions’ comments.

Hoffman’s confidence stems from a statement by federal attorney Andrew Lelling. Lelling is a prosecutor who reports directly to Attorney General Sessions. And two weeks ago, Lelling issued a statement that, from Hoffman’s view, sounded a lot like the Cole Memo guidance issued by Obama’s DOJ.

According to Lelling, federal prosecutors are prioritizing three areas of marijuana law enforcement. First, ensuring legal cannabis surpluses aren’t diverted to illegal markets. Second, targeting operators who distribute cannabis to minors. And finally, hunting down criminal organizations that traffic cannabis across state lines.

Hoffman says Massachusetts regulators are already building in ways to address the Department of Justice’s major concerns. He believes that will be enough to keep Massachusetts out of Sessions’ drug-war crosshairs.
This Jeff Session is thinking wrongly?
 
"Her anti-marijuana views can't be very helpful in Washington, one of the first three states in America to legalize recreational marijuana. And her views may finally be catching up to her. McMorris Rodgers is currently in a tight electoral race that shows she's in a toss-up with Democrat Lisa Brown."
If you want to understand a politicians actions and stated positions....just look to their self-interest. Its all that motivates them. So, once again we have a politician moving toward support of legal cannabis...why? Cause she's about to get her ass kicked in the mid-terms. Same with Cuomo running against Nixon and a number of other examples. Self-interest in DC trumps all other considerations.


Republican leader in congress questions Jeff Sessions' policy towards marijuana

A high-ranking member of Republican congressional leadership is finally coming out and questioning Attorney General Jeff Sessions' marijuana policy, writes Joseph Misulonas. Cathy McMorris Rodgers, a Republican congresswoman from Washington, said she "leans against" Sessions' decision earlier this year to rescind the Cole Memo, a Department of Justice policy saying the federal government will not interfere with states that legalize marijuana. She also says marijuana "maybe" should be rescheduled by the federal government.

McMorris Rodgers is currently the head of the House Republican Conference, which helps select party leadership, approve committee assignments and other responsibilities. As head of the conference, she's the fourth highest ranking Republican in the House of Representatives.

However it's likely that McMorris Rodgers' comments are not quite authentic. Despite them, she's voted against protecting states with legalized recreational or medical marijuana nearly every time it's come to vote during her tenure in office. And on top of that, she's been part of the Republican leadership that's prevented marijuana bills from receiving votes in the House.

Her anti-marijuana views can't be very helpful in Washington, one of the first three states in America to legalize recreational marijuana. And her views may finally be catching up to her. McMorris Rodgers is currently in a tight electoral race that shows she's in a toss-up with Democrat Lisa Brown. In fact, just yesterday The Atlantic wrote that McMorris Rodgers is the most likely member of the Republican leadership who will not be re-elected this November.

So perhaps McMorris Rodgers is simply making these pro-marijuana comments as a way to prevent cannabis enthusiasts from voting against her this November.

How much do you want to bet if she gets re-elected that she'll go right back to doing nothing for marijuana?
 
So, I'm not allowed to call anybody names anymore (well, never was allowed, tbh)...even somebody as deserving as old El Jeffe. So, I will just comment with a picture LOL :buzz:

upload_2018-9-11_12-5-1.jpeg




Members of Congress demand Jeff Sessions approve more growers for marijuana research

Since taking office in 2017, Jeff Sessions has not been a friend of the legal cannabis industry. From threatening to crack down on retail stores in legal states to refusing to allow more institutions to grow for research reasons, his approach to the industry is forcing members of Congress on both sides to push back.

Two different letters were sent to Sessions on August 31 urging him to approve applications to grow cannabis for research. Sessions announced a new Department of Justice policy in 2016 that would increase the number of institutions that would grow cannabis for research purposes, but two years later, that still has yet to happen.

There is currently only one person in the United States who is allowed to grow cannabis for research purposes and that is Mahmoud ElSohly, a researcher at the University of Mississippi.

“ElSohly’s monopoly, sustained only by the Justice Department’s refusal to approve new applicants, poses an insurmountable obstacle for American academics and drug companies,” writes Mike Riggs for Reason.

Clinical Trials using ElSohly’s product are not being approved creating a barrier for academics wanting to conduct studies with the products that people are already buying at retail locations all over the United States. As such, politicians are pushing Sessions to make a move.

One of the letters, signed by 15 members of Congress said, “In light of the fact that August 11, 2018 marked two years since the Drug Enforcement Administration (DEA) stated that they would accept registrations for manufacturers of marijuana for research usage, we write to encourage you to finalize your review of the submitted applications.” Republican Congress members who signed the letter included Carlos Curbelo, Matt Gaetz, Dana Rohrabacher, Don Young, Tom Garrett and Ryan Costello.

The other letter, sent by Republican Senator Orrin Hatch and Democratic Senator Kamala Harrris requested that Sessions finally respond to a letter that was sent earlier in April that asked for a timeline for when the research applications would be approved.

According to Reason, 15 separate letters have been sent to Jeff Sessions by members of Congress about the applications for new cannabis growers, seven of which have been posted publically or shared by those who signed them. Sessions has not responded to any of these letters.
 
Ding dong the witch is dead, the wicked witch, the witch is dead. Trump asked and got his resignation today.

Also, Pete Sessions....major league cannabis legislation blocker as chairman of the rules committee, lost his re-election bid. He wouldn't be chairman in any case any longer, but he got...IMO...what he deserves for his anti-democratic actions (MOM....did you notice...I never called him a single name.....but I'm blue from holding my breath! haha)


Sessions #2.JPG
 


BREAKING NEWS: Anti-cannabis advocate Jeff Sessions forced out as attorney general by Trump

Attorney General Jeff Sessions was pushed out Wednesday as the country’s chief law enforcement officer.

Cannabis stocks, already bolstered by wins in the midterm elections, got an added boost when anti-pot Attorney General Jeff Sessions announced his resignation Wednesday afternoon.

Exchange-traded funds that track marijuana stocks, including the Horizons Marijuana Life Sciences Index ETF in Toronto and the U.S.-listed ETFMG Alternative Harvest ETF, jumped to fresh highs on the news, gaining 7 per cent and 6.2 per cent respectively.

Tilray Inc. saw the biggest surge, climbing as much as 25 per cent in its biggest gain since Sept. 19, when the stock almost doubled before giving back most of the gains in a wild ride for investors. Other cannabis-related stocks in both the U.S. and Canada also gained.

Sessions was a major foe of marijuana legalization, moving last January to rescind an Obama-era policy that allowed states to make their own decisions on cannabis without interference from the federal government. That announcement sent pot shares plunging three days after California became the largest jurisdiction to legalize recreational use.

Cannabis stocks were broadly higher Wednesday after Michigan voted to legalize recreational marijuana and Missouri approved medical pot. The Democrats’ House of Representatives win was also thought to be a positive catalyst for stocks, making legal reform more likely.

Sessions told the president in a one-page letter that he was submitting his resignation “at your request.”

Trump announced in a tweet that he was naming Sessions’ chief of staff Matthew Whitaker, a former United States attorney from Iowa, as acting attorney general.

The resignation was the culmination of a toxic relationship that frayed just weeks into the attorney general’s tumultuous tenure, when he stepped aside from the investigation into potential coordination between the president’s Republican campaign and Russia.

Trump blamed the decision for opening the door to the appointment of special counsel Robert Mueller, who took over the Russia investigation and began examining whether Trump’s hectoring of Sessions was part of a broader effort to obstruct justice and stymie the probe.

The implications for Mueller’s investigation were not immediately clear. The Justice Department did not announce a departure for Deputy Attorney General Rod Rosenstein, who appointed Mueller more than a year and a half ago and has closely overseen his work since then.

The relentless attacks on Sessions came even though the Alabama Republican was the first U.S. senator to endorse Trump and despite the fact that his crime-fighting agenda and priorities — particularly his hawkish immigration enforcement policies — largely mirrored the president’s.

But the relationship was irreparably damaged in March 2017 when Sessions, acknowledging previously undisclosed meetings with the Russian ambassador and citing his work as a campaign aide, recused himself from the Russia investigation.

Story Continues Below



The decision infuriated Trump, who repeatedly lamented that he would have never selected Sessions if he had known the attorney general would recuse. The recusal left the investigation in the hands of Rosenstein, who appointed Mueller as special counsel two months later after Trump fired then-FBI Director James Comey.

The rift lingered for the duration of Sessions’ tenure, and the attorney general, despite praising the president’s agenda and hewing to his priorities, never managed to return to Trump’s good graces.

The deteriorating relationship became a soap opera stalemate for the administration. Trump belittled Sessions but, perhaps following the advice of aides, held off on firing him. The attorney general, for his part, proved determined to remain in the position until dismissed. A logjam broke when Republican senators who had publicly backed Sessions began signaling a willingness to consider a new attorney general.

In attacks delivered on Twitter, in person and in interviews, Trump called Sessions weak and beleaguered, complained that he wasn’t more aggressively pursuing allegations of corruption against Democratic rival Hillary Clinton and called it “disgraceful” that Sessions wasn’t more serious in scrutinizing the origins of the Russia investigation for possible law enforcement bias — even though the attorney general did ask the Justice Department’s inspector general to look into those claims.

The broadsides escalated in recent months, with Trump telling a television interviewer that Sessions “had never had control” of the Justice Department and snidely accusing him on Twitter of not protecting Republican interests by allowing two GOP congressmen to be indicted before the election.

Sessions endured most of the name-calling in silence, though he did issue two public statements defending the department, including one in which he said he would serve “with integrity and honor” for as long as he was in the job.

The recusal from the Russia investigation allowed him to pursue the conservative issues he had long championed as a senator, often in isolation among fellow Republicans.

He found satisfaction in being able to reverse Obama-era policies that he and other conservatives say flouted the will of Congress, including by encouraging prosecutors to pursue the most serious charges they could and by promoting more aggressive enforcement of federal marijuana law. He also announced media leak crackdowns, tougher policies against opioids and his Justice Department defended a since-abandoned administration policy that resulted in parents being separated from their children at the border.

His agenda unsettled liberals who said that Sessions’ focus on tough prosecutions marked a return to failed drug war tactics that unduly hurt minorities and the poor, and that his rollbacks of protections for gay and transgender people amount to discrimination.

Some Democrats also considered Sessions too eager to do Trump’s bidding and overly receptive to his grievances.

Sessions, for instance, directed senior prosecutors to examine potential corruption in a uranium field transaction that some Republicans have said may have implicated Clinton in wrongdoing and benefited donors of the Clinton Foundation. He also fired one of the president’s primary antagonists, former FBI deputy director Andrew McCabe, just before he was to have retired — a move Trump hailed as a “great day for democracy.”

Despite it all, Sessions never found himself back in favor with the president.

Their relationship wasn’t always fractured. Sessions was a close campaign aide, attending national security meetings and introducing him at rallies in a red “Make America Great Again” hat.

But the problems started after he told senators during his confirmation hearing that he had never met with Russians during the campaign. The Justice Department, responding to a Washington Post report, soon acknowledged that Sessions had actually had two encounters during the campaign with the then-Russian ambassador. He recused himself the next day, saying it would be inappropriate to oversee an investigation into a campaign he was part of.

The announcement set off a frenzy inside the White House, with Trump directing his White House counsel to call Sessions beforehand and urge him not to step aside. Sessions rejected the entreaty. Mueller’s team, which has interviewed Sessions, has been investigating the president’s attacks on him and his demands to have a loyalist in charge of the Russia investigation.

Sessions had been protected for much of his tenure by the support of Senate Republicans, including Judiciary Committee Chairman Chuck Grassley, who had said he would not schedule a confirmation hearing for another attorney general if Trump fired him.

But that support began to fade, with Grassley suggesting over the summer that he might have time for a hearing after all.

And Republican Sen. Lindsey Graham, another Judiciary Committee member who once said there’d be “holy hell to pay” if Trump fired Sessions, called the relationship “dysfunctional” and said he thought the president had the right after the midterm to select a new attorney general.
 
https://420intel.com/articles/2018/...ff-sessions-forced-out-attorney-general-trump
BREAKING NEWS: Anti-cannabis advocate Jeff Sessions forced out as attorney general by Trump

Attorney General Jeff Sessions was pushed out Wednesday as the country’s chief law enforcement officer.

Cannabis stocks, already bolstered by wins in the midterm elections, got an added boost when anti-pot Attorney General Jeff Sessions announced his resignation Wednesday afternoon.

Exchange-traded funds that track marijuana stocks, including the Horizons Marijuana Life Sciences Index ETF in Toronto and the U.S.-listed ETFMG Alternative Harvest ETF, jumped to fresh highs on the news, gaining 7 per cent and 6.2 per cent respectively.

Tilray Inc. saw the biggest surge, climbing as much as 25 per cent in its biggest gain since Sept. 19, when the stock almost doubled before giving back most of the gains in a wild ride for investors. Other cannabis-related stocks in both the U.S. and Canada also gained.

Sessions was a major foe of marijuana legalization, moving last January to rescind an Obama-era policy that allowed states to make their own decisions on cannabis without interference from the federal government. That announcement sent pot shares plunging three days after California became the largest jurisdiction to legalize recreational use.

Cannabis stocks were broadly higher Wednesday after Michigan voted to legalize recreational marijuana and Missouri approved medical pot. The Democrats’ House of Representatives win was also thought to be a positive catalyst for stocks, making legal reform more likely.

Sessions told the president in a one-page letter that he was submitting his resignation “at your request.”

Trump announced in a tweet that he was naming Sessions’ chief of staff Matthew Whitaker, a former United States attorney from Iowa, as acting attorney general.

The resignation was the culmination of a toxic relationship that frayed just weeks into the attorney general’s tumultuous tenure, when he stepped aside from the investigation into potential coordination between the president’s Republican campaign and Russia.

Trump blamed the decision for opening the door to the appointment of special counsel Robert Mueller, who took over the Russia investigation and began examining whether Trump’s hectoring of Sessions was part of a broader effort to obstruct justice and stymie the probe.

The implications for Mueller’s investigation were not immediately clear. The Justice Department did not announce a departure for Deputy Attorney General Rod Rosenstein, who appointed Mueller more than a year and a half ago and has closely overseen his work since then.

The relentless attacks on Sessions came even though the Alabama Republican was the first U.S. senator to endorse Trump and despite the fact that his crime-fighting agenda and priorities — particularly his hawkish immigration enforcement policies — largely mirrored the president’s.

But the relationship was irreparably damaged in March 2017 when Sessions, acknowledging previously undisclosed meetings with the Russian ambassador and citing his work as a campaign aide, recused himself from the Russia investigation.

Story Continues Below



The decision infuriated Trump, who repeatedly lamented that he would have never selected Sessions if he had known the attorney general would recuse. The recusal left the investigation in the hands of Rosenstein, who appointed Mueller as special counsel two months later after Trump fired then-FBI Director James Comey.

The rift lingered for the duration of Sessions’ tenure, and the attorney general, despite praising the president’s agenda and hewing to his priorities, never managed to return to Trump’s good graces.

The deteriorating relationship became a soap opera stalemate for the administration. Trump belittled Sessions but, perhaps following the advice of aides, held off on firing him. The attorney general, for his part, proved determined to remain in the position until dismissed. A logjam broke when Republican senators who had publicly backed Sessions began signaling a willingness to consider a new attorney general.

In attacks delivered on Twitter, in person and in interviews, Trump called Sessions weak and beleaguered, complained that he wasn’t more aggressively pursuing allegations of corruption against Democratic rival Hillary Clinton and called it “disgraceful” that Sessions wasn’t more serious in scrutinizing the origins of the Russia investigation for possible law enforcement bias — even though the attorney general did ask the Justice Department’s inspector general to look into those claims.

The broadsides escalated in recent months, with Trump telling a television interviewer that Sessions “had never had control” of the Justice Department and snidely accusing him on Twitter of not protecting Republican interests by allowing two GOP congressmen to be indicted before the election.

Sessions endured most of the name-calling in silence, though he did issue two public statements defending the department, including one in which he said he would serve “with integrity and honor” for as long as he was in the job.

The recusal from the Russia investigation allowed him to pursue the conservative issues he had long championed as a senator, often in isolation among fellow Republicans.

He found satisfaction in being able to reverse Obama-era policies that he and other conservatives say flouted the will of Congress, including by encouraging prosecutors to pursue the most serious charges they could and by promoting more aggressive enforcement of federal marijuana law. He also announced media leak crackdowns, tougher policies against opioids and his Justice Department defended a since-abandoned administration policy that resulted in parents being separated from their children at the border.

His agenda unsettled liberals who said that Sessions’ focus on tough prosecutions marked a return to failed drug war tactics that unduly hurt minorities and the poor, and that his rollbacks of protections for gay and transgender people amount to discrimination.

Some Democrats also considered Sessions too eager to do Trump’s bidding and overly receptive to his grievances.

Sessions, for instance, directed senior prosecutors to examine potential corruption in a uranium field transaction that some Republicans have said may have implicated Clinton in wrongdoing and benefited donors of the Clinton Foundation. He also fired one of the president’s primary antagonists, former FBI deputy director Andrew McCabe, just before he was to have retired — a move Trump hailed as a “great day for democracy.”

Despite it all, Sessions never found himself back in favor with the president.

Their relationship wasn’t always fractured. Sessions was a close campaign aide, attending national security meetings and introducing him at rallies in a red “Make America Great Again” hat.

But the problems started after he told senators during his confirmation hearing that he had never met with Russians during the campaign. The Justice Department, responding to a Washington Post report, soon acknowledged that Sessions had actually had two encounters during the campaign with the then-Russian ambassador. He recused himself the next day, saying it would be inappropriate to oversee an investigation into a campaign he was part of.

The announcement set off a frenzy inside the White House, with Trump directing his White House counsel to call Sessions beforehand and urge him not to step aside. Sessions rejected the entreaty. Mueller’s team, which has interviewed Sessions, has been investigating the president’s attacks on him and his demands to have a loyalist in charge of the Russia investigation.

Sessions had been protected for much of his tenure by the support of Senate Republicans, including Judiciary Committee Chairman Chuck Grassley, who had said he would not schedule a confirmation hearing for another attorney general if Trump fired him.

But that support began to fade, with Grassley suggesting over the summer that he might have time for a hearing after all.

And Republican Sen. Lindsey Graham, another Judiciary Committee member who once said there’d be “holy hell to pay” if Trump fired Sessions, called the relationship “dysfunctional” and said he thought the president had the right after the midterm to select a new attorney general.
Hooray!
 

https://www.theguardian.com/us-news/2018/nov/07/matthew-whitaker-trump-attorney-general-us-firm

@ataxian, don't get too excited. Session's replacement, Matthew Whitaker, is a real piece of work. He's a trump loyalist who has said that the Mueller probe is a witch hunt and already has a plan to shut it down. He's also an extreme partisan.
He worked for a company that the U.S. said was scamming customers and the company was ordered to pay a 26 million dollar settlement. He also threatened a customer that emailed World Patent Marketing about being ripped off.

donald trump’s new acting attorney general was part of a company accused by the US government of running a multimillion-dollar scam.
Matthew Whitaker was paid to sit on the advisory board of World Patent Marketing, which was ordered in May this year to pay a $26m settlement following legal action by federal authorities, which said it tricked aspiring inventors.
In May this year, a judgment requiring World Patent Marketing to pay the government $25,987,192 was entered against the company by a federal court in southern Florida.

https://www.theguardian.com/us-news/2018/nov/07/matthew-whitaker-trump-attorney-general-us-firm
 
https://www.theguardian.com/us-news/2018/nov/07/matthew-whitaker-trump-attorney-general-us-firm

@ataxian, don't get too excited. Session's replacement, Matthew Whitaker, is a real piece of work. He's a trump loyalist who has said that the Mueller probe is a witch hunt and already has a plan to shut it down. He's also an extreme partisan.
He worked for a company that the U.S. said was scamming customers and the company was ordered to pay a 26 million dollar settlement. He also threatened a customer that emailed World Patent Marketing about being ripped off.

donald trump’s new acting attorney general was part of a company accused by the US government of running a multimillion-dollar scam.
Matthew Whitaker was paid to sit on the advisory board of World Patent Marketing, which was ordered in May this year to pay a $26m settlement following legal action by federal authorities, which said it tricked aspiring inventors.
In May this year, a judgment requiring World Patent Marketing to pay the government $25,987,192 was entered against the company by a federal court in southern Florida.

https://www.theguardian.com/us-news/2018/nov/07/matthew-whitaker-trump-attorney-general-us-firm
4-me I am very happy to have him out 4-his view’s R many centuries behind the need’s of the people.
Muller will be fine!
 
This article is actually from last May... but I thought it might be a good way to 'close the door' on this thread. :biggrin:

Inconsolable Jeff Sessions Tries To Commit Suicide By Smoking Joint


u7ddu3celqazf2rhq8xc.jpg


WASHINGTON—Following months of bruising criticism from Democrats and President Trump alike, an inconsolable Jeff Sessions was reportedly trying to commit suicide Thursday by smoking a joint. “I swore I’d never take the coward’s way out, but what choice do I have?” said a teary-eyed Sessions, carefully laying a sealed envelope containing his farewell note on a tool bench in his garage as he raised a lighter to the marijuana cigarette with trembling hands. “This is it. I’ve taken four puffs to make sure there’s no chance of survival. It should only be a matter of minutes now. Oh, what a wretched, ignominious ending. Goodbye, cruel world, I’m sorry I’ve failed you so.” At press time, Sessions reportedly realized he had died after being overcome by a euphoric, floating feeling.
 
4-me I am very happy to have him out 4-his view’s R many centuries behind the need’s of the people.
Muller will be fine!

Whitaker is also anti cannabis. He does see some benefit to limited medical use. More importantly, he makes false statments when it comes to cannabis.

Whitaker then turned to the Justice Department’s marijuana policy under President Barack Obama’s attorney general, Eric Holder.

“But what we have is we have an attorney general that is telling state attorney generals [sic], ‘if you disagree with a law, you don’t have to enforce it.’
And I am gravely concerned that we are now going to go back and forth between who’s in the White House and what their drug enforcement policy is, and you’ll see under what we have now — where you have Colorado and other states legalizing it really with no federal interference — and then when we come back, we may have a different regulatory scheme.”

“For me, I saw the impact of marijuana on our border,” he said, presumably referring to his time as a U.S. attorney. “And if you go to any of the counties in Texas where there’s an illegal importation of marijuana, there’s a tremendous amount of violence.”
 
Last edited:
Whitaker is also anti cannabis. He does see some benefit to limited medical use. More importantly, he makes false statments when it comes to cannabis.

Whitaker then turned to the Justice Department’s marijuana policy under President Barack Obama’s attorney general, Eric Holder.

“But what we have is we have an attorney general that is telling state attorney generals [sic], ‘if you disagree with a law, you don’t have to enforce it.’
And I am gravely concerned that we are now going to go back and forth between who’s in the White House and what their drug enforcement policy is, and you’ll see under what we have now — where you have Colorado and other states legalizing it really with no federal interference — and then when we come back, we may have a different regulatory scheme.”

“For me, I saw the impact of marijuana on our border,” he said, presumably referring to his time as a U.S. attorney. “And if you go to any of the counties in Texas where there’s an illegal importation of marijuana, there’s a tremendous amount of violence.”
Fucking idiots
 
  • Like
Reactions: BD9
Fuck you @Baron23.

Mod note: Warning point issued.
 
Last edited by a moderator:
Status
Not open for further replies.

Sponsored by

VGoodiez 420EDC
Back
Top